- Home
- IBRX vs PPTA Comparison
IBRX vs PPTA Comparison
Compare IBRX & PPTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PPTA
- Stock Information
- Founded
- IBRX 2014
- PPTA 2011
- Country
- IBRX United States
- PPTA United States
- Employees
- IBRX N/A
- PPTA N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PPTA Precious Metals
- Sector
- IBRX Health Care
- PPTA Basic Materials
- Exchange
- IBRX Nasdaq
- PPTA Nasdaq
- Market Cap
- IBRX 2.3B
- PPTA 2.9B
- IPO Year
- IBRX N/A
- PPTA N/A
- Fundamental
- Price
- IBRX $2.26
- PPTA $22.65
- Analyst Decision
- IBRX Strong Buy
- PPTA Strong Buy
- Analyst Count
- IBRX 6
- PPTA 4
- Target Price
- IBRX $9.83
- PPTA $25.38
- AVG Volume (30 Days)
- IBRX 9.4M
- PPTA 4.4M
- Earning Date
- IBRX 11-10-2025
- PPTA 11-17-2025
- Dividend Yield
- IBRX N/A
- PPTA N/A
- EPS Growth
- IBRX N/A
- PPTA N/A
- EPS
- IBRX N/A
- PPTA N/A
- Revenue
- IBRX $56,600,000.00
- PPTA N/A
- Revenue This Year
- IBRX $629.94
- PPTA N/A
- Revenue Next Year
- IBRX $109.91
- PPTA N/A
- P/E Ratio
- IBRX N/A
- PPTA N/A
- Revenue Growth
- IBRX 4227.22
- PPTA N/A
- 52 Week Low
- IBRX $1.83
- PPTA $7.81
- 52 Week High
- IBRX $5.88
- PPTA $31.65
- Technical
- Relative Strength Index (RSI)
- IBRX 39.09
- PPTA 47.21
- Support Level
- IBRX $2.30
- PPTA $22.97
- Resistance Level
- IBRX $2.67
- PPTA $26.00
- Average True Range (ATR)
- IBRX 0.12
- PPTA 2.16
- MACD
- IBRX -0.02
- PPTA -0.49
- Stochastic Oscillator
- IBRX 1.19
- PPTA 1.59
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PPTA Perpetua Resources Corp.
Perpetua Resources Corp is focused on the exploration, site restoration, and redevelopment of gold-antimony-silver deposits in the Stibnite-Yellow Pine district of central Idaho that are encompassed by the Stibnite Gold Project. The Project is one of the highest-grade, open-pit gold deposits in the United States and is designed to apply a modern, responsible mining approach to restore an abandoned mine site and produce both gold and the only mined source of antimony in the United States. It has one segment, mineral exploration in the United States.